GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Cash Receipts from Operating Activities

NeuroSense Therapeutics (NeuroSense Therapeutics) Cash Receipts from Operating Activities


View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
11 HaMenofim Street, Building B, Herzliya, ISR, 4676670
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.